“However, Figure 2 … indicates that the aspirin placebo subgroup, but not the 2 active aspirin subgroups (81 mg/d and …), seemed to be associated with an increased frequency of advanced lesions in the folic acid group during the first follow-up interval, … did not appear to reach statistical significance.”
“We suggest that the authors assess whether this possible interaction between aspirin and folic acid intake exists in the second follow-up interval, because it is possible that a residual effect of 3 years of aspirin intake would persist for another 3 to 5 years.”